-
ESTIMATING REAL-WORLD PERSISTENCE TO CARDIOMETABOLIC MEDICATION IN PEOPLE WITH TYPE 2 DIABETES TO INFORM AN EARLY HTA: A CAREPATH STUDY
Aug 11, 2026, 17:16 PM -
THE EMA ACCELERATED ASSESSMENT PROCEDURE AND ITS IMPLICATIONS FOR THE NATIONAL ITALIAN ACCESS PATHWAY
Aug 11, 2026, 17:16 PM -
ASSESSING THE PUBLIC HEALTH IMPACT OF BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: QALY RESULTS FROM A BRAZILIAN PERSPECTIVE
Aug 11, 2026, 17:16 PM -
DIRECT HEALTHCARE COST BURDEN OF POST-STROKE SPASTICITY IN GREECE
Aug 11, 2026, 17:16 PM -
LOW-COST FEATURE EXTRACTION FROM CLINICAL NOTES USING HUMMINGBIRD: ECOG PERFORMANCE STATUS OF LUNG CANCER PATIENTS
Aug 11, 2026, 17:16 PM -
GEOGRAPHIC VARIATION IN HOW PHYSICIANS CONCEPTUALISE, ASSESS AND ACT ON DISEASE ACTIVITY AND PROGRESSION IN MULTIPLE SCLEROSIS: A REAL-WORLD MULTI-COUNTRY SURVEY
Aug 11, 2026, 17:16 PM -
THE CURRENT STATUS OF SOCIAL CARE-RELATED QUALITY OF LIFE FOR PEOPLE WITH DISABILITIES IN JAPAN
Aug 11, 2026, 17:16 PM -
AI-DRIVEN ISPOR-SMDM VALIDATION OF AN EXCEL-BASED COST-EFFECTIVENESS MODEL
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFICACY OF BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE VERSUS BECLOMETHASONE DIPROPIONATE/GLYCOPYRRONIUM/FORMOTEROL FUMARATE IN UNCONTROLLED ASTHMA: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)
Aug 11, 2026, 17:16 PM -
BENCHMARKING IMPOWER133 AND EXTENDING EVIDENCE TO ECOG PS2 PATIENTS USING A REGISTRY-BASED TARGET TRIAL EMULATION
Aug 11, 2026, 17:16 PM -
FOUNDATIONS BEFORE INTEGRATION: STAKEHOLDER PRIORITIES FOR HTA DEVELOPMENT IN SLOVENIA IN THE ERA OF THE EU HTA REGULATION
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF MALE SLING AND ARTIFICIAL URINARY SPHINCTER FOR URETHRAL SPHINCTER DEFICIENCY IN THAILAND
Aug 11, 2026, 17:16 PM -
GLOBAL REGULATORY CHALLENGES AND PATIENT SAFETY CONCERNS IN NEW-AGE TECHNOLOGY-BASED MEDICAL DEVICES A SCOPING REVIEW
Aug 11, 2026, 17:16 PM -
MOST FAVOURED NATION, LEAST FAVOURED MARKETS? EU5 PAYER PERSPECTIVES ON US PRICING REFORMS
Aug 11, 2026, 17:16 PM -
THE COST PER RESPONDER OF BIMEKIZUMAB VERSUS RISANKIZUMAB IN PSORIATIC ARTHRITIS (PSA)
Aug 11, 2026, 17:16 PM -
PROCUREMENT AND EXPENDITURE TRENDS OF ORPHAN AND NON-ORPHAN HIGH-COST MEDICINES DISPENSED THROUGH PUBLIC OUTPATIENT PHARMACIES IN GREECE, 2020-2025
Aug 11, 2026, 17:16 PM -
UTILIZATION AND EXPENDITURE TRENDS OF MEDICINES DISPENSED THROUGH PUBLIC OUTPATIENT PHARMACIES IN GREECE: A COMPARISON OF SPECIAL ACCESS AND STANDARD PATHWAYS 2020-2025
Aug 11, 2026, 17:16 PM -
A STRUCTURED FRAMEWORK FOR CONFOUNDER IDENTIFICATION: A CAUSAL INFERENCE APPROACH FOR LOCALIZED OR LOCALLY ADVANCED HIGH-RISK PROSTATE CANCER
Aug 11, 2026, 17:16 PM -
UNDERSTANDING EMPLOYMENT AND FINANCIAL CHALLENGES OF CARE PARTNERS OF PEOPLE WITH ALZHEIMER'S DISEASE AND OTHER DEMENTIAS: A MULTI-COUNTRY MIXED METHODS STUDY
Aug 11, 2026, 17:16 PM -
CONVERGENCE OR PLURALISM? TRACKING METHODOLOGICAL TRENDS IN EARLY EU JOINT CLINICAL ASSESSMENTS
Aug 11, 2026, 17:16 PM
